Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three-part PK and PD study of AXN-027
NL-OMON61308Phase 1Recruiting
- Sponsor
- Axonis Therapeutics
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of AXN-027 in chronic pain, epilepsy and Excitation/inhibition imbalance-associated neurological disorders, sponsored by Axonis Therapeutics. Started Jun 2026; status: recruiting.
02
Drugs
AXN-027
03
Conditions
chronic painepilepsyExcitation/inhibition imbalance-associated neurological disorders
Beyond the preview
Go deeper on NL-OMON61308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61308.